Switching from infliximab‐originator to infliximab‐biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy Apre una nuova scheda del browser
(2019)
Inizio contenuto principale del sito
(2019)
(2019)
(2019)
(2019)
(2019)
(2019)
(2019)
(2019)
(2019)
(2019)